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ABSTRACT
Pharmacokinetics of Dexamethasone Delivered via Iontophoresis
Justin H. Rigby
Department of Exercise Sciences, BYU
Doctor of Philosophy
Study Design: Controlled laboratory study. Objectives: To determine the time course of
dexamethasone sodium phosphate (Dex-P) iontophoresis delivery to underlying tissues using
microdialysis. Background: The efficacy of iontophoresis at delivering Dex-P through the skin
is unknown in humans because of the lack of minimally invasive measurement techniques.
Methods: Sixty-four healthy male participants (age = 24.4 ± 3.3 yrs, height = 71.8 ± 2.5 in,
weight = 181.8 ± 26.1 lbs) were randomly assigned into one of six groups: 1) 1 mA current, 1
mm probes depth; 2) 1 mA current, 4 mm probes depth; 3) 2 mA current, 1 mm probes depth; 4)
2 mA current, 4 mm probes depth; 5) in vivo retrodialysis; and 6) skin perfusion flowmetry.
Microdialysis probes assess the combined recovery (Dextotal) of Dex-P, dexamethasone (Dex)
and its metabolite. In vivo calibration of the microdialysis probes occurred via retrodialysis.
Laser Doppler flowmetry assessed skin perfusion. Results: There was no difference of Dextotal
between current intensities (P = 0.99) but a greater amount of Dextotal was recovered by the 1 mm
probe (P < 0.0001) compared to the 4 mm probe. Peak means for the 1 and 2 mA at 1 mm were
10.8 ± 8.1 and 7.7 ± 5.5 μg/ml and at 4mm being 2.0 ± 0.8 and 1.3 ± 0.9 μg/ml, respectively.
Skin perfusion rapidly increased during both current intensity treatments, but significantly
decreased before the conclusion of the 1 mA treatment (P < 0.0001). Peak skin perfusion was
741.4 ± 408.7% and 711.6 ± 260.8% baseline for 1 and 2 mA intensities, respectively.
Conclusion: Iontophoresis delivery of Dex-P was successful measured in vivo through human
skin. Significant concentrations of Dextotal were found regardless of current intensity. Though
current induced vasodilation occurred, it did not significantly affect the tissue accumulation of
Dextotal.
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INTRODUCTION
Iontophoresis is a transdermal drug delivery system which uses a direct, or galvanic,
current to transfer ions through the skin to underlying tissues. Dexamethasone sodium phosphate
(Dex-P) delivered via iontophoresis is commonly used in physical medicine and rehabilitation to
treat tendinopathies, however, this procedure has inconsistent clinical outcomes.1,8,18,21-23,25,28,33
Research designed to examine Dex-P iontophoresis efficacy has been lacking due to
methodological limitations.
Using animal models, initial research has demonstrated the effectiveness of Dex-P
iontophoresis at delivering the drug across the epidermis6,12,24 but without accumulation in
venous blood.5 However, the human epidermis has structural differences from animal models
making a true evaluation of Dex-P iontophoresis effects on humans unclear with animal models.
In vivo human studies are limited by an inability to monitor tissue levels of Dex-P with
minimally invasive techniques. Researchers use indirect methods such as assessing skin
blanching characteristics2 and venous blood draws31 to examine Dex-P delivery. One group of
researchers directly measured the concentration of Dex-P in underlying tissues after an
iontophoresis treatment using tissue biopsies.13,14 After a 40 mA*min iontophoresis treatment
with Dex-P to the semitendinosus, Gurney et al13 found Dex-P in some but not all biopsy
samples.
The inability to adequately characterize Dex-P delivery to underlying tissue during
iontophoresis leaves us with insufficient data to help optimize iontophoresis parameters and
thereby limits our ability to explain the inconsistencies in clinical outcomes. We use a minimally
invasive technique, intradermal microdialysis, to sample the accumulation of Dex-P, its
biologically active form (dexamethasone, Dex) and its metabolites during iontophoresis delivery.
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Microdialysis is a method used to sample local exogenous or endogenous compounds
from interstitial fluid. Microdialysis involves perfusing a probe, which has a semi-permeable
membrane, with a physiological solution (perfusate) allowing equilibration between the perfusate
and interstitial fluid. Equilibration of an analyte occurs through a diffusion gradient between the
interstitial fluid and perfusate resulting in a dialysate containing our analyte of interest.30 Our lab
has used this technique successfully to examine transdermal drug delivery of lidocaine.9,10
One aim of this study was to quantify the time course of Dex-P iontophoresis delivery
through the skin (at 1 and 4 mm depth) at current intensities of 1 and 2 mA using intradermal
microdialysis. Based upon current theories for drug delivery with iontophoresis we tested the
well accepted hypothesis15 that the tissue accumulation of Dex in the underlying skin will follow
a similar time course when plotted as a function of iontophoresis dose (mA*min) regardless of
the applied current intensity.
METHODS
Participants
We recruited 64 healthy males (age = 24.2 ± 3.3 y, height = 181.8 ± 26.1 cm, mass =
82.4 ± 11.8 kg, subcutaneous fat thickness = 0.61 ± 0.19 cm). Females were excluded from this
study because of potential side-effects of Dex-P on fetal development in pregnant women. Male
participants were also kept from participating if they had one or more of the following
conditions: a known allergy to Dex, diabetes, an infection or open wound on the posterior lower
leg, decreased circulation or sensitivity in the area to be treated, or an injury to either lower
extremity within the previous 2 mo.
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The study was approved by Brigham Young University’s Institutional Review Board
before participant recruitment. All participants provided written informed consent before
individual data collection began.
Instruments and Dialysate Analysis
We used the Triviarion iontophoresis delivery kit (ActivaTek Inc., Salt Lake City, UT) to
deliver Dex-P to the treatment site. The drug-delivery (cathode) electrode (12.56 cm2) was
prepared with 2 ml of 0.4% Dex-P while the center of the dispersive (positive) electrode
(37.5 cm2) was placed 15 cm distal to the Dex-P filled cathode electrode. We used an IontophorII phoresor (model: 6111PM/DX, Life-Tech Inc., Stafford,TX) to deliver the iontophoresis
treatment.
The 18 kilo-Dalton linear (3.0 cm) hollow fiber microdialysis probes (150 micron OD)
were manufactured in our laboratory per instructions described previously by other
researchers9,10 and gas sterilized with ethylene oxide. We used an infusion pump (model: Pump
11 VPF; Harvard Apparatus, Holliston, MA) to perfuse the microdialysis probes with sterile
saline. The depth of the inserted microdialysis probe was verified using musculoskeletal
ultrasound imaging (model: LogiQ P5, probe type: 12L, General Electric Company, Fairfield,
CT).
The concentrations of Dex-P, Dex and its metabolites in each dialysate sample was
determined by reverse-phase high performance liquid chromatography (RP-HPLC) using a
previously established method.7 A diode array detector (model: 1260 Infinity, Agilent
Technologies, Inc., Santa Clara, CA) with a wavelength of 239 nm was used to measure the
peaks of Dex-P and DEX at 4.2 and 12.4 min, respectively. The lower limit quantification of
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Dex-P and Dex was 100 ng/mL and 50 ng/mL, respectively. The standard curves for each
analyte is shown in FIGURE 1. Analysis of dialysis samples by RP-HPLC revealed a peak at
5.8 min which represented the Dex metabolite, dexamethasone-21-oic acid (Dex-21-oic acid),
and was quantified using a combination of the Dex-P and Dex calibration curve.
Skin perfusion was measured via laser Doppler flowmetry (LDF). Four laser Doppler
skin probes (model: VP7a, Moore Instruments, Wilmington, DE) were interfaced with a laser
Doppler monitor (Moore Instruments, Wilmington, DE). The laser Doppler output was
monitored using Powerlab (ADInstruments Inc., Colorado Springs, CO) in order to measure
changes in skin perfusion.
Procedures
Participants reported to the lab for a single visit. Participants were screened for the
inclusion and exclusion criteria. Each reviewed and signed the Institutional Review Board
approved consent form. Once officially enrolled in the study, the participants were randomly
assigned to one of the six groups: 1) 1 mA current intensity with probes depth of 1 mm, n = 8;
2) 1 mA current intensity with probes depth of 4 mm, n = 8; 3) 2 mA current intensity with
probes depth of 1 mm, n = 8; 4) 2 mA current intensity with probes depth of 4 mm, n = 8;
5) in vivo retrodialysis of Dex-P and Dex, n = 8 ; and 6) skin blood flowmetry, n = 24. We chose
to insert the deep probes at a depth of 4 mm because the approximate depth of commonly treated
tendons is 4 mm below the surface of the skin.4
Microdialysis Probe Placement for Dex-P and Dex Recovery during Iontophoresis
Three linear microdialysis probes were inserted in the left posterior lower leg at the depth
based on the participant’s group assignment. During the microdialysis probe placement,
participants lay prone on a treatment table. An 8” x 8” area on the left posterior lower leg of the
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participant was shaved. We visualized the largest girth of the participant’s lower leg. Marks were
made on the participant’s posterior lower leg indicating where the guide needles would be
inserted and exit. From the surface of the skin on the posterior lower leg, we measured down the
medial side 1 or 4 mm (based on group assignment) and made a mark with a felt marker. From
this mark, we measured lateral 5 cm and made a mark where the probe would exit the lower leg.
The insertion and exit sites were then cleansed with an iodine swab.
Using aseptic procedures, three sterile 3.5 in. 27 gauge pediatric spinal tap needles
(reference 405081, BD Company, Franklin Lakes, NJ) were inserted into the subcutaneous tissue
of the participant’s left posterior lower leg at the marked sites, either 1 or 4 mm below the
surface of the skin (actual depth = 1.3 ± 0.3 or 4.0 ± 0.7 mm). The depth of each needle was
verified using musculoskeletal ultrasound imaging. The microdialysis probes were fed through
each guide needle and the guide needles were removed leaving the probes in place in the lower
leg. Once the probes were inserted, sterile saline solution was perfused through the probe at
1.2 µl/min for 60 min and collected as the pretreatment dialysate. This period allowed the tissue
to recover from the mild trauma associated with the guide needle insertion.
Once the 60 min recovery period was complete, the prepared drug-delivery electrode was
placed on the skin directly over the microdialysis probes. The dispersive electrode was placed
15 cm distally from the drug delivery electrode. The iontophoresor leads were attached to the
respective electrode and the unit was turned on to deliver the iontophoresis treatment based on
the participant’s group assignment (1mA or 2mA for 120 mA*min). Starting with the initiation
of Dex-P iontophoresis, dialysate from each microdialysis probe was collected in 15 min
intervals (1mA group = 8 samples and 2 mA group = 4 samples) with the perfusion rate
maintained at 1.2 µl/min. After the treatment was completed, we collected an additional 4
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dialysate samples at 15 min intervals. Immediately after each collection period, dialysate samples
were stored at -20°C until they were analyzed using RP-HPLC.
Microdialysis Probe Placement for Dex-P and Dex Retrodialysis
Retrodialysis is an in vivo microdialysis calibration technique based on the theory that in
vivo loss represents in vivo recovery. During retrodialysis, the microdialysis probe was perfused
with the analytes of interest (2 µg/mL of Dex-P and Dex) at the same perfusion rate (1.2 µl/min)
and the dialysate was monitored for the disappearance of the analyte from the probe. The relative
recovery (RR) was then calculated as a percent.30,32
�𝐷𝑟𝑢𝑔

�

𝑅𝑅 = �1 − �𝐷𝑟𝑢𝑔 𝑑𝑖𝑎𝑙𝑦𝑠𝑎𝑡𝑒 � � 𝑥 100
𝑝𝑒𝑟𝑓𝑢𝑠𝑎𝑡𝑒

Participants randomly assigned to the retrodialysis group had a single microdialysis probe

inserted into their left posterior lower leg using the same insertion techniques as described earlier
(depth = 3.2 ± 1.4 mm). This microdialysis probe was perfused with sterile saline at 1.2 μL/min
for 60 min as a recovery period. Following the recovery period, sterile saline with 2 μg/mL of
Dex-P and 2 μg/mL of Dex-P was perfused through the microdialysis probe at 1.2 μL/min. Three
dialysates were collected at 45 min intervals and were analyzed with RP-HPLC.
RP-HPLC Analysis
For consistency, standard curves of Dex-P and Dex concentrations were analyzed both
prior to and at the conclusion of collecting all dialysis samples. The mean standard curves were
used to determine the concentrations of Dex-P and Dex in each dialysis sample.
Skin Perfusion Monitoring
Four LDF probes were attached to the posterior lower leg of the participants randomly
assigned to the skin blood flow group. The flow probes were placed within the drug delivery
chamber (adjacent to the center electrode, 0 cm), on the periphery of the drug chamber (2 cm
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away from center of electrode), on the periphery of the electrode (4 cm away from center of
electrode) and between the active and dispersive electrodes (6 cm away from center of
electrode). The placements of the probes are visualized in FIGURE 2. The skin of the posterior
lower leg was cleaned with isopropyl alcohol and the iontophoresis electrodes and LDF probes
were then applied. Baseline skin perfusion was established during a 5-min stabilization period.
Then, a 120 mA*min iontophoresis treatment with Dex-P was applied with a current intensity of
either 1 (n = 12) or 2 (n = 12) mA. The treatment was randomly assigned and lasted 120 or
60 min, respectively. Skin perfusion was monitored and instantaneously recorded throughout the
treatment and for an additional 60 min after the treatment. Heart rate and blood pressure was also
measured and recorded every 10 min throughout the treatment and posttreatment.
Data Analysis
We used the area under the RP-HPLC generated peaks at migration times of 4.2, 5.9 and
12.4 min to represent the concentration of Dex-P, Dex-21-oic acid, Dex, respectively, in each
dialysate sample. Using the RP-HPLC standard curves and our retrodiaylsis RR, we calculated
the total amount of Dex delivered to the tissue or Dextotal (Dextotal = Dex-P + Dex + Dexmetabolite)
for each sample. Skin perfusion was normalized by dividing the flux reading (mV) by the mean
arterial blood pressure (mmHg). Changes in skin perfusion were expressed as a percent change
in skin perfusion relative to baseline. All variables (Dextotal and skin perfusion) were plotted as a
function of iontophoresis dose.
Statistical Analysis
A 4 x 5 (group x dose) mixed model ANOVA was used to determine differences between
the intensities and depths of Dextotal over the iontophoresis treatment. Due to our timing of
sample collection, we could only compare the groups at 30 mA*min dose increments.
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A 2 x 13 (intensity x dose) mixed model ANOVA was used to determine differences
between skin perfusion and intensities over the iontophoresis dose within the drug delivery
electrode (0 cm). We only show the data for skin perfusion at the 0 cm site because there was no
visible change in skin perfusion at the other sites. We compared the group differences in skin
perfusion at 10 mA*min dose increments.
We used JMP Pro 10 (SAS Inc., Cary, NC) for all statistical analyses and alpha was set at
P < 0.05.
RESULTS
The retrodialysis recovery indicated that the microdialysis probes collected 27.4 ± 2.0%
of Dextotal in the extracellular fluid in vivo. Using the standard curve and retrodialysis recovery
values, the accumulation of Dextotal as a function of iontophoresis dose is shown in FIGURE 3
for the different current intensities and probe depths.
We did not recover a substantial amount of Dex-P from the underlying tissues. We
recovered Dex in only six of 32 participants with mean concentration of 109.9 ± 88.8 ng/mL
representing only 2.92% of all Dextotal. The majority of Dextotal recovered by intradermal
microdialysis was the Dex metabolite, Dex-21-oic acid. The Dex metabolite was recovered in all
subjects across all samples.
A greater amount of Dextotal was recovered by the 1mm probes compared to the 4mm
probes across the final 60 mA*min to 120 mA*min of the iontophoresis treatment (F12,112 = 5.21,
P < 0.0001). Peak Dextotal at 120 mA*min and 1 mm probe depth for the 1 and 2 mA treatments
were similar and averaged 10.8 ± 8.1 and 7.7 ± 5.5 μg/ml, respectively. Averaged between
intensities, this represents approximately 0.23% of the Dex-P placed in the iontophoresis
chamber. At 4 mm probe depth and 120 mA*min dose Dextotal was similar and averaged
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2.0 ± 0.8 and 1.3 ± 0.9 μg/ml, for 1 and 2 mA current intensities, respectively. At any given
probe depth Dextotal was similar for both 1 and 2 mA current intensities across all iontophoresis
dosages (P > 0.05).
Skin perfusion increased rapidly during both iontophoresis treatment intensities,
however, the 1 mA current intensity group showed a significant decrease in skin perfusion before
the iontophoresis treatment was over (F12,264 = 23.17, P < 0.0001) (FIGURE 4). Peak skin
perfusion of 741.4 ± 408.7% baseline during 1 mA treatments occurred at 40 mA*min. During
2 mA treatments, peak skin perfusion of 711.6 ± 260.8% baseline occurred at 110 mA*min. Skin
perfusion returned to baseline values during the 1 mA treatment intensity at 110 mA*min. While
skin perfusion returned to baseline in the 2 mA intensity group 60 min after terminating the
iontophoresis protocol.
DISCUSSION
By combining intradermal microdialysis and RP-HPLC, we successfully measured in
vivo extracellular Dextotal accumulation at 1 and 4 mm depth in the dermis during iontophoresis
in human participants. Earlier studies monitored only Dex concentrations and found little or no
accumulation of Dex in tissue underlying the iontophoresis site. For example, Gurney and
Wascher,13,14 used tissue biopsies to measure in vivo Dex accumulation. However, only 7 out of
16 participants had any measureable levels of Dex in the biopsy sample of the semitendinosus
tendon 85-235 min after a 40 mA*min iontophoresis treatment. In the 7 samples that Dex was
detected the mean concentration was 6.6 ± 3.2 ng/g.14 Similarly, we recovered Dex in only 6 of
32 participants with a mean concentration of 109.9 ± 88.8 ng/mL. However, this represented
only a small fraction (< 3%) of Dextotal. The major Dex component of our dialysate samples was
the Dex metabolite, Dex-21-oic acid.
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Dex-P is an anionic prodrug with an ester link at the 21 carbon to increase the aqueous
solubility of Dex. Mammalian skin contains esterases which hydrolyzes Dex-P into Dex.24 Based
on our HPLC analysis,7 the metabolite product of the iontophoresis delivery of Dex-P was
exclusively Dex-21-oic acid. As such, Dex-P does not appear to completely hydrolyze into pure
Dex, but instead into an acid ester form. Dex-21-oic acid has a lower affinity for binding to the
glucocorticoid receptor and has a diminished anti-inflammatory potential compared to Dex.17 To
our knowledge, our study was the first to report a metabolite conversion of Dex-P when
delivered through human skin. Animal models have reported a more pure conversion rate of
Dex-P to Dex in cerebrospinal fluid and plasma.20,29
During the iontophoresis treatment, tissue levels of Dextotal easily exceeded the minimally
effective dose for Dex. Heiss et al16 established the ED50 (minimally effective dose) of Dex as
75 ng/g indicating that small concentrations of Dex have anti-inflammatory effect. Dextotal
concentrations at both measurement depths surpassed the minimally effective dose of Dex within
the first 15 mA*min. However, Dex-21-oic acid has a lower affinity for the glucocorticoid
receptor. Though we noted Dextotal greater than the minimally effective dose for Dex, it is
unclear what the minimal dose of Dex-21-oic acid is needed to provide sufficient antiinflammatory action.
The assumption of iontophoresis is that the drug concentration delivered through the skin
is linearly proportional to the applied iontophoresis dose, which is defined as the current
intensity multiplied by the treatment time.26 Under this assumption, Dextotal should be similar at
the same iontophoresis dose, regardless of current intensity. We found similar tissue levels of
Dextotal during 1 and 2 mA treatment intensities. These data provide in vivo data to support the
widely held expectation that transdermal drug delivery by iontophoresis is depended almost

11
exclusively by iontophoresis dose. Our data refutes speculation by Anderson et al2 that smaller
iontophoresis intensity may drive more Dex into the tissue. Anderson et al2 indirectly assessed
Dex delivery by measuring skin blanching, a vasoconstriction reaction attributed by Dex, after a
40 mA*min iontophoresis treatment, they noted that greater skin blanching occurring for a
longer period of time and with greater magnitude when lower current intensities (0.05 to
0.16 mA) were used.
During the constant influx of drug ions during iontophoresis, passive diffusion and
washout by blow flow is to be expected. In animal models, iontophoresis delivery creates a depot
of the drug in the outer layers of the epidermis.24 In addition, it appears that the delivery of
anionic drugs via the cathode produces a greater depot development than anode delivery of
drugs.19,27 The anionic drug Dex-P competes with chloride ions during iontophoresis. The small
molecular weight of chloride ions facilitates the direct current to carry these ions deeper into the
tissue thereby leaving the larger Dex-P ions to form a depot in the epidermis.2,34 Deeper
penetration of Dex-P is hypothesized to occur by passive diffusion and/or convective transport
by the microvasculature system.2 There was a noticeably smaller amount of Dextotal at the 1 mm
site, but not an increase in Dextotal at the deeper 4 mm site after the 120 mA*min iontophoresis
treatment. It is likely that tissue clearance of Dextotal by the microvasculature system prevented
any immediate diffusion mediated increase in Dextotal at the 4 mm sample site. Gurney et al14
noted an association between extraction time and Dex concentration. At the semitendinosus
tendon, greater Dex was associated with a longer extraction time, indicating that it may take
several hours for passive diffusion of the drug to occur.
Cathodal iontophoresis produces cutaneous vasodilation. Berlinger3 reported that the
superficial vasculature increased 700% from baseline during cathode iontophoresis. The large
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increase in skin perfusion at the cathode is approximately 75% of the maximum cutaneous
vascular conductance.11 These results are similar to our findings. However, in the 1 mA current
intensity group skin perfusion began to return to baseline at approximately 40 mA*min and
eventually reached baseline levels before the end of the iontophoresis treatment. In contrast, skin
perfusion remained elevated throughout the 2 mA current treatment and returned to baseline only
after the iontophoresis was terminated, requiring at least 60 min to return to baseline.
Current induced vasodilation, noted in cathode iontophoresis, is thought to be mediated
by an axon reflex. The current induces primary afferent fiber excitation of C fibers creating a
release of its vasodilator neurochemicals, such as substance P and calcitonin gene-related
peptides.35 Also, the production of prostaglandins is stimulated during direct current
iontophoresis leading to vasodilation. Prostaglandins are also involved in hyper-sensitizing
receptors located on small sensory neurons lowering the firing threshold of these neurons,
creating an amplified current induced vasodilation.35 As noted, we found differences in skin
perfusion between our current intensities. It is possible that the 1 mA current stimulated afferent
nerves fibers and resulted in the initial vasodilator response, but habituation occurred resulting in
a reduced vasodilator signal. Conversely, the 2 mA current maintained current induced
vasodilation throughout the treatment. More interesting is that the differences in current induced
vasodilation between our two current intensities did not significantly affect the concentration of
Dextotal in the tissues. Future research is needed to understand if greater current intensities would
produce sufficient vasodilation to actually impact drug delivery to the underlying tissues.
Variations in our methods from previous studies13,14,31 allowed us to monitor several
time points during iontophoresis delivery to characterize the rate of accumulation of Dex in
human tissue. First, we used a longer iontophoresis dose than the majority of studies. Anderson
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et al2 and Gurney and Wascher13 used 40 mA*min iontophoresis doses, while we used a 120
mA*min dose. Our iontophoresis delivery system did not produce any skin burns with this high
dose. However, our maximum current intensity was only 2.0 mA (current density = 0.16
mA/cm2). Second, we measured Dextotal found in the extracellular fluid space using
microdialysis. Microdialysis provided us a method to measure the time course of tissue
accumulation of Dex. The lower leg provided us a safe place to insert the microdialysis probes,
but some assumptions of the iontophoresis delivery and pharmacodynamics were made. We
assumed that the iontophoresis delivery and pharmacodynamics of Dex-P through the stratum
corneum at the posterior lower leg would be similar as if done at common treatment sites over a
tendon. We also assumed a greater concentration of Dextotal would lead to greater cellular and
clinical outcome responses.
Limitations
Our study has limitations. We used healthy individuals in order to describe the delivery
characteristics of Dex-P when delivered via iontophoresis at two different current intensities. We
assume that the delivery of Dex-P through the skin would be similar in an injured population.
Our results are limited to inferences made between the two current intensities, 1 and 2 mA,
which we selected.
Future Research
A comprehensive examination of all iontophoresis parameters in an effort to optimize
drug delivery has yet to be performed in human participants. Future studies using different
current intensities and different iontophoresis devices (i.e. wired phoresors vs. wireless patches)
is required to establish effective parameters for clinical iontophoresis of Dex-P.
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CONCLUSION
Using microdialysis, we successfully measured transdermal drug delivery of Dex-P over
the course of an iontophoresis treatment in vivo through human skin. When delivered through
human skin Dex-P accumulated primarily as the hydrolyzed and less potent Dex metabolite,
Dex-21-oic acid. However, based on the significant concentrations of Dextotal, compared to the
minimally effective dose of Dex, which was recovered at 1 and 4 mm tissue depths, we believe
Dex-P iontophoresis to be an effective modality at treating tendonitis conditions. Dextotal
recovery increased throughout the iontophoresis treatment at similar rates between the 1 and 2
mA current intensities indicating no difference in drug delivery between our high and low
current intensities. Current induced vasodialation was prolonged throughout the treatment when
treating with 2 mA current intensity, but did not significantly affect the tissue accumulation of
Dextotal.
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FIGURE 1. RP-HPLC standard curves of dexamethasone sodium phosphate (Dex-P),
dexamethasone (Dex) and their combined standard curve for Dexamethasone-21-oic acid
calculation. Each point represents the mean area under the absorbance (239 nm) time curve
(AUC) of duplicate runs.
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FIGURE 2. Placement of laser Doppler flowmeter probes to measure skin perfusion during
iontophoresis treatment. Laser Doppler flowmeter probes were placed inside the drug chamber (0
cm), just outside the drug chamber (2 cm) and 4 and 6 cm from the center of the drug electrode.
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FIGURE 3. Dextotal concentrations (Dextotal = Dexamethasone sodium phospate+Dexamethason+Dexamethasone-21-oic acid) between
1 and 2 mA intensities and different depth over a 120 mA*min iontophoresis dose. Values are mean ± 1 SEM for 8 participants in
each group. ∗= Indicates significant difference of Dextotal between 1 and 4 mm at a given current intensity (p<0.05).
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Figure 4. Superficial skin perfusion response of 1 and 2 mA current intensities during a 120 mA*min iontophoresis dose. Vales are
mean ± 1 SEM for 12 participants in each group. ∗ = Indicates significant difference between 1 and 2 mA treatment intensities
(p<0.05).
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Appendix A
Reverse-Phase Higher Performance Liquid Chromatography Methods
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Instrument Model: Agilent 1260 (Agilent Technologies Inc., Santa Clara, CA)
Column: Zorbax eclipse XDB-C8 4.6 x 150 mm 5μm
Binary Pump (model: G1212B)
Flow: 0.650 mL/min
Use solvent types: Yes
Low pressure limit: 0.30 bar
High pressure limit: 600.00 bar
Maximum flow gradient: 100.00 mL/min2
Stop time: 17.00 min
Post time: 1.00 min
Solvent: Aminium formade (20mM) / acetonitrile (70/30) in pH 3.8 adjusted with formic acid
Sampler (model: G1329B)
Draw speed: 200.00 μL/min
Ejection speed: 200.00 μL/min
Injection volume: 20.00 μL
Column Comp.
Temperature: 45.0° C
DAD (model: G4212B)
Peakwidth: >0.10 min (2.0 sec response time)
Signals
A. Wavelength: 239.0 nm (reference 360 nm)

